Potassium channels in atrial fibrillation: Targets for atrial and pathology-specific therapy?

Heart Rhythm

Volumn 5, Issue 5, 2008, Pages 758-759

  Ravens, Ursula ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Atrial fibrillation; Potassium channels; Remodeling; Therapeutic implications

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; AVE 0188; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DOFETILIDE; MUSCARINIC RECEPTOR; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; SODIUM CHANNEL; TERTIAPIN; VERNAKALANT;

ACTION POTENTIAL; ARTICLE; DOWN REGULATION; DRUG EFFICACY; HEART ATRIOVENTRICULAR NODE; HEART ATRIUM FIBRILLATION; HEART MUSCLE REFRACTORY PERIOD; HEART REPOLARIZATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; QT PROLONGATION; RECEPTOR BLOCKING;

ACTION POTENTIALS; ANIMALS; ATRIAL FIBRILLATION; HUMANS; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS;

EID: 42749086457     PISSN: 15475271     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hrthm.2007.11.008     Document Type: Article

References (16)

1. Wijffels M.C., Kirchhof C.J., Dorland R., et al. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 92 (1995) 1954-1968
2. Nattel S., Maguy A., Le Bouter S., et al. Arrhythmogenic ion-channel remodeling in the heart: heart failure, myocardial infarction, and atrial fibrillation. Physiol Rev 87 (2007) 425-456
3. Dobrev D., and Ravens U. Remodeling of cardiomyocyte ion channels in human atrial fibrillation. Basic Res Cardiol 98 (2003) 137-148
4. Pandit S.V., Berenfeld O., Anumonwo J.M., et al. Ionic determinants of functional reentry in a 2-D model of human atrial cells during simulated chronic atrial fibrillation. J. Biophys J 88 (2005) 3806-3821
5. Fuster V., Ryden L.E., Cannom D.S., et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 8 (2006) 651-745
6. Lombardi F., and Terranova P. Pharmacological treatment of atrial fibrillation: mechanisms of action and efficacy of class III drugs. Curr Med Chem 13 (2006) 1635-1653
7. Kur in controlling action potential shape and contractility in the human atrium: influence of chronic atrial fibrillation. Circulation 110 (2004) 2299-2306
8. Kur), fully restores atrial contractility after cardioversion of atrial fibrillation in the goat. Circulation 114 (2006) 1234-1242
9. to in rapid atrial pacing in rabbits. J Am Coll Cardiol 41 (2003) 858-869
10. Fedida D. Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent. Expert Opin Investig Drugs 16 (2007) 519-532
11. Nattel S. New ideas about atrial fibrillation 50 years on. Nature 415 (2002) 219-226
12. K,ACh in atrial fibrillation using a mouse knockout model. J Am Coll Cardiol 37 (2001) 2136-2143
13. K,ACh and muscarinic receptor-mediated shortening of action potentials. Circulation 104 (2001) 2551-2557
14. K,ACh is constitutively active in patients with chronic atrial fibrillation. Circulation 112 (2005) 3697-3706
15. Cha T.J., Ehrlich J.R., Chartier D., et al. Kir3-based inward rectifier potassium current: potential role in atrial tachycardia remodeling effects on atrial repolarization and arrhythmias. Circulation 113 (2006) 1730-1737
16. Coplen S.E., Antman E.M., Berlin J.A., et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation 82 (1990) 1106-1116